Fresenius Group Overview

  • Q3 & Q1-3/2017 Results

    Fresenius reports another strong quarter and confirms guidance

New Developments

Financial Highlights


€ 8.3 bn


Q3/2016: €7.4 bn


€ 1481 m


Q3/2016: €1,373 m


€ 1129 m


Q3/2016: €1,071 m



Dec. 31, 2016: 232,873

Net Income2

€ 423 m


Q3/2016: €382 m

Earnings per Share2

€ 0.77


Q3/2016: €0.69


1 In constant currency

2 Before acquisition-related expenses

3 Net income attributable to shareholders of Fresenius SE & Co. KGaA; consistent with scope of original guidance: before acquisition-related expenses; before expenditures for further development of biosimilars business

CEO message

“We can report another very good quarter, once again boosted by strong sales and earnings growth. The prospects for our businesses remain excellent. We are therefore confirming our guidance and are heading towards yet another record year. From this position of strength, we intend to swiftly close and integrate our strategically important acquisitions. Thus, we are expanding our range of high-quality, affordable healthcare products and services for the benefit of our patients and our company.”

Stephan Sturm, Chairman of the Management Board 

  • Business Segments

    • Solid Q3 despite impact from natural disasters in North America
    • 8% constant currency sales growth in Q3
    • 2017 outlook confirmed1

    1 Excluding effects of VA agreement and natural disaster costs

  • Business Segments

    • 7% organic sales growth in Q3; positive contributions from all regions
    • 11% adjusted EBIT growth1 in constant currency in Q3
    • 2017 outlook confirmed

    1 Consistent with scope of original guidance: before acquisition-related expenses; before expenditures for further development of biosimilars business

  • Business Segments

    • 47% sales growth (4% excluding Quirónsalud) in Q3
    • 33% EBIT increase (9% excluding Quirónsalud) in Q3
    • 2017 outlook confirmed

  • Business Segments

    • 9% sales growth in service business in Q3
    • Project business with strong order intake of €285 million in Q3
    • 2017 outlook confirmed

Acquisition of Akorn and Merck KGaA’s biosimilars business

Fresenius Kabi to strengthen and diversify product portfolio by acquiring Akorn and Merck KGaA’s biosimilars business

„From a position of strength, Fresenius Kabi enhances and complements its business with two major steps. Akorn is an excellent strategic fit for Fresenius Kabi. The company’s product portfolio is highly complementary to our well-developed generics business. The simultaneous entry into the biosimilars business is the right step into the right direction at the right time. The acquired biosimilars assets are an attractive opportunity for Fresenius Kabi to enter this strongly growing and highly profitable segment. Both acquisitions are milestones on Fresenius Kabi’s growth path for this decade and beyond.“

Stephan Sturm, Chairman of the Management Board
  • Akorn shareholders approve merger agreement

    • Closing expected latest by early 2018
    • The shareholders of Akorn, Inc., have approved the merger agreement with Fresenius Kabi, with 83.9% of outstanding shares being voted in favour of the transaction.
    • This corresponds to 99.7% of common shares represented in person or by proxy at the Special Meeting.
    • The transaction remains subject to additional customary closing conditions, including regulatory review under the Hart-Scott-Rodino Antitrust Improvements Act in the U.S.
  • Acquisition of Akorn

    Fresenius Kabi has agreed to acquire Akorn, Inc., a U.S.-based manufacturer and marketer of prescription and over-the-counter pharmaceutical products, for US$34 per share equivalent to US$4.3 billion, plus approximately US$450 million1 of net debt.

    1 Based on projected net debt of US$450 million as of December 31, 2017

  • About Akorn

    Akorn produces and markets a diverse product portfolio of injectables, topical creams, ointments and gels, sterile ophthalmics, as well as oral liquids, otic solutions (for the ear), nasal sprays and respiratory drugs. Akorn products are sold in retail pharmacies (prescription and over-the-counter) and directly to physicians, in addition to hospitals and clinics – almost exclusively in the U.S.
  • Highlights of Akorn acquisition

    • Complementary product portfolio and pipeline diversifies Fresenius Kabi’s IV generics offering
    • Access to additional distribution channels: retail, clinics and physicians
    • Adds growth potential in attractive adjacent segments such as ophthalmology and clinical dermatology
    • Substantial cost and growth synergies paired with limited integration complexity
  • Fresenius submits first biosimilar Marketing Authorization Application

    Fresenius Kabi has submitted a Marketing Authorization Application to the European Medicines Agency for its adalimumab biosimilar candidate of Humira®. The application is the first biosimilar regulatory filing for Fresenius Kabi. Adalimumab is approved in the EU for use in the treatment of chronic inflammatory autoimmune conditions, including different types of arthritis or Crohn's disease.
  • Fresenius Kabi completes acquisition of Merck KGaA’s biosimilars business

    The transaction comprises the entire development pipeline of Merck’s biosimilars and an experienced team of employees located in Aubonne and Vevey, Switzerland. The product pipeline has a focus on oncology and autoimmune diseases, and addresses a market with current annual branded sales of around US$30bn. The biosimilars business will be consolidated as of September 1, 2017.
  • Highlights of Merck KGaA's biosimilars business acquisition

    • Strategic step to enhance Fresenius Kabi’s position as a leading player in the injectable pharmaceuticals market
    • Direct access to attractive biosimilars development platform
    • Experienced team of biosimilars experts with excellent development know-how 


All Financial Reports